Other authors have shown that SOX-2 expression might be molecularly targeted by drugging proteins, such as the deubiquitinase USP9x with neogambogic acid [216] and STAT3 signaling with apatinib [217], which then leads to inhibition of stemness features, including expression of Oct-4 and NANOG, and increase chemosensitivity in osteosarcoma cells. The gene discussed is SOX2; the disease is osteosarcoma.